p53 expression in carcinoma of the cervix

Journal of Clinical Pathology

Volumn 49, Issue 12, 1996, Pages 971-974

  Hunt, C R ^a   Hale, R J ^b   Buckley, C H ^a   Hunt, J ^c  

^a ST MARY S HOSPITAL   (United Kingdom)

^b STEPPING HILL HOSPITAL   (United Kingdom)

^c UNIVERSITY OF MANCHESTER   (United Kingdom)

Author keywords

Cervical carcinoma; P53; Prognosis

Indexed keywords

PROTEIN P53;

ADENOCARCINOMA; ADENOSQUAMOUS CARCINOMA; ARTICLE; FEMALE; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; PRIORITY JOURNAL; PROGNOSIS; SQUAMOUS CELL CARCINOMA; UTERINE CERVIX CARCINOMA;

EID: 0030428702     PISSN: 00219746     EISSN: None     Source Type: Journal    
DOI: 10.1136/jcp.49.12.971     Document Type: Article

References (35)

1. Levine AJ, Momand J, Finlay CA. The p53 tumour suppressor gene. Nature 1991;351:453-6.
2. Finlay CA, Hinds PN, Levine AJ. The p53 proto-oncogene can act as a suppressor of transformation. Cell 1989;57: 1083-93.
3. Hollstein M, Sidransky D, Vogelstein B, Harris CC. p53 mutations in human cancers. Science 1991;253:49-53.
4. Bartek J, Bartkova J, Vojtesek B, Stakova Z, Lukas J, Rejthar A, et al. Aberrant expression of the p53 oncoprotein is a common feature of a wide spectrum of human malignancies. Oncogene 1991;6:1699-703.
5. Levine AJ, Perry ME, Chang A, Silver A, Dittmer D, Wu M, et al. The 1993 Walter Hubert Lecture: the role of the p53 tumour suppressor gene in tumorigenesis. Br J Cancer 1994;69:409-16.
6. Starzynska T, Bromley M, Gosh A, Stern PL. Prognostic significance of p53 over-expression and c-Ki-ras mutations in colorectal cancer. Gastroenterology 1993;104:57-64.
7. Vijeyasingam R, Darnton SJ, Jenner K, Allen CA, Billingham C, Matthews HR. Expression of p53 protein in oesophageal carcinoma: clinicopathological correlation and prognostic significance. Br J Surg 1994;81:1623-6.
8. Barnes DM, Dublin EA, Fisher CJ, Levison DA, Millis RA. Immunohistochemical detection of p53 protein in mammary carcinoma: an important new independent indicator of prognosis? Hum Pathol 1993;24:469-79.
9. Miwa K, Miyamoto S, Kato H, Imamura T, Nishida M, Yoshikawa Y, et al. The role of p53 inactivation in human cervical cell carcinoma development. Br J Cancer 1995;71: 219-26.
10. Crook T, Wrede D, Tidy JA, Mason WP, Evans DJ, Vousden KH. Clonal p53 mutations in primary cervical cancer: association with human papillomavirus negative tumours. Lancet 1992;339:1070-3.
11. Park SY, Kang YS, Kim BG, Lee SH, Lee ED, Lee KH, et al. Loss of heterozygosity on the short arm of chromosome 17 in uterine cervical carcinoma. Cancer Genet Cytogenet 1995; 79:74-8.
12. Scheffner M, Werness BA, Huibregtse JM, Levine AJ, Howley PM. The E6 oncoprotein encoded by human papillomavirus type 16 and 18 promotes the degradation of p53. Cell 1990;63:1129-36.
13. Buckley CH, Fox H. Carcinoma of the cervix. In: Anthony PP, MacSween RNM, eds. Recent advances in histopathology. Vol 14. London: Churchill Livingstone, 1989:63-78.
14. Hale RJ, Wilcox FL, Buckley CH, Tindall VR, Ryder WDJ, Logue JP. Prognostic factors in uterine cervical carcinoma: a clinico-pathological analysis. Int J Gynecol Cancer 1991;1:19-23.
15. Bornstein J, Rahat MA, Abramovici H. Etiology of cervical cancer: current concepts. Obstet Gynecol Surv 1995;50: 146-54.
16. Wank R, Thomssen C. High risk of squamous cell carcinoma of the cervix for women with HLA-DQw3. Nature 1991;352:723-5.
17. Gupta JW, Saito K, Fu YS, Shah K. Human papillomaviruses and the pathogenesis of cervical neoplasia. Cancer 1989;64:2104-10.
18. Blondal JA, Benchimol S. The role of p53 in tumor progression. Semin Cancer Biol 1994;5:177-86.
19. Baas IO, Mulder JR, Offerhaus GFA, Vogelstein B, Hamilton SR. An evaluation of six antibodies for immunohistochemistry of mutant p53 gene product in archival colorectal neoplasms. J Pathol 1993;172:5-12.
20. Holm R, Skomedal H, Heiland A, Kristensen G, Borresen AL, Nesland JM. Immunohistochemical analysis of p53 protein overexpression in normal, premalignant and malignant tissues of the cervix uteri. J Pathol 1993;169:21-6.
21. Helland A, Holm R, Kristensen G, Kaern J, Karlsen F, Trope C, et al. Genetic alterations of the TP53 gene, p53 protein expression and HPV infection in primary cervical carcinomas. J Pathol 1993;171:105-14.
22. Lambkin HA, Mothersill CM, Kelehan P. Variations in immunohistochemical detection of p53 protein overexpression in cervical carcinomas with different antibodies and different methods of detection. J Pathol 1993;172:13-18.
23. Paquette RL, Lee YY, Wilczynski SP, Karmakar A, Kizaki M, Miller CW, et al. Mutations of p53 and human papillomavirus infection in cervical carcinoma. Cancer 1993;72: 1272-80.
24. Oka K, Nakano T, Arai T. p53CM1 expression is not associated with prognosis in uterine cervical carcinoma. Cancer 1993;72:160-3.
25. Kainz C, Kohlberger P, Gitsch G, Sliutz G, Breitenecker G, Reinthaller A. Mutant p53 in patients with invasive cervical cancer stages IB to IIB. Gynecol Oncol 1995;57:212-14.
26. Busby-Earle RMC, Steel CM, Williams ARW, Cohen B, Bird CC. p53 mutations in cervical carcinogenesis low frequency and lack of correlation with human papillomavirus status. Br J Cancer 1994;69:732-7.
27. Bosari S, Roncalli M, Viale G, Bossi P, Coggi G. p53 immunoreactivity in inflammatory and neoplastic diseases of the uterine cervix. J Pathol 1993;169:425-30.
28. Lane DP. p53, guardian of the genome. Nature 1992;358: 15-16.
29. Oliner JD, Kinzler KW, Meltzer PS, George DL, Vogelstein B. Amplification of a gene encoding a p53-associated protein in human sarcomas. Nature 1992;358:705-8.
30. Butz K, Shahabeddin L, Giesen C, Spitkovsky D, Ullman A, Hoppe-Seyler F. Functional p53 protein in human papillomavirus-positive cancer cells. Oncogene 1995;10: 927-36.
31. Park DJ, Wilczynski SP, Paquette RL, Miller CW, Koeffler HP. p53 mutations in HPV-negative cervical carcinoma. Oncogene 1994;9:205-10.
32. Gitsch G, Kainz C, Joura H, Beitenecker G. Mutant p53 in patients with stage III cervical cancer. Anticancer Res 1992; 12:2241-2.
33. Wynford-Thomas D. p53 in-tumour pathology: Can we trust immunocytochemistry? J Pathol 1992;166:329-30.
34. Hall PA, Lane DP. p53 in tumour pathology: Can we trust immunohistochemistry?... Revisited! J Pathol 1994;172:1-4.
35. Dowell SP, Hall PA. The p53 tumour suppressor gene and tumour prognosis: Is there a relationship? J Pathol 1995;177:221-4.